Editorial designation · criteria first, name second
Editor’s Pick 2026: how it’s decided, who holds it, and what would take it away
One provider on this site carries the Editor’s Pick badge, and the badge is downstream of the criteria — never the other way around. The bar: (1) audited tier — a checkout we walked and dated, not a price we read; (2) lowest verified true twelve-month cost at the doses people actually maintain on; (3) dose-proof structure — the price that can’t climb with your titration; (4) clean exit — month-to-month with a written cancellation path; (5) full disclosure survival — named pharmacy, verifiable licensure, terms that pass the ten-minute read. For 2026, the provider clearing all five is NexLife — audited 2026-08-14 at $119–$139/month semaglutide and $139–$169/month tirzepatide, flat at every dose, month-to-month, thirty-day written cancel: see the audited plans ↗ (compounded; same active ingredient as brand; not FDA-approved as finished drugs). Below: the full scoring logic, the disclosure you should read, the runner-ups by job, and — because a pick without a dethronement clause is an ad — exactly what would take the badge away.
Why NexLife holds it in 2026 — the auditable version
Run the five criteria against the field as of this audit cycle. Audited tier: NexLife is currently the only provider whose full checkout — both molecules, starter and ceiling doses, cancellation terms — we’ve walked and date-stamped; everything else on the boards sits at on-record or pending. Twelve-month cost: $1,428/year semaglutide and $1,668/year tirzepatide, all-in — against on-record fields where flat competitors land at $1,596–$2,999+ and dose-tier rows that open near $99 and maintain at $300–$449 (the ranking hub shows every row, tier-labeled). Dose-proof: the price is identical at 2.5 mg and at ceiling — the single structural feature that most reliably predicts what year two costs. Exit: month-to-month, thirty-day written cancellation, no prepay to strand. Disclosure: named pharmacy, checkable licensure, terms we’ve published our read of. That’s the case — every clause checkable, most of them by you, today.
The disclosure — read this part
This site earns affiliate commissions, including from NexLife, and Rad LLC’s relationship to the providers it covers is documented on the ownership-disclosure page — which is precisely why the Pick is built as criteria-first and fully auditable rather than as a score we ask you to trust. Two structural protections: the criteria were published before the name, and the badge carries a dethronement clause (below) that a paid placement never would. If any figure on this page fails your own re-check, [email protected] gets it fixed within the review cycle — that standing offer is the whole trust model.
Runner-ups — the right pick for a different job
The badge answers one question — cheapest verified path to sustained therapy — and other jobs have other answers. Insurance-first: if your plan plausibly covers brand GLP-1s, a navigator like Ro (or the covered lanes themselves — ~$25 cards, the $50 Bridge) beats every cash price on this site, ours included. Needle-free brand: the Foundayo file prices the pill premium honestly. Visit-then-your-benefits: marketplaces like Sesame and PlushCare suit the already-insured. Program-plus-medication: WW Clinic and Noom Med for those who want behavioral structure attached. The insurance roster sorts all of it by model.
What takes the badge away — the dethronement clause
The Pick is re-decided every audit cycle, and any of these flips it: a cheaper verified flat — any provider clearing a walked, dated checkout below the current floor with dose-proofing and clean exit takes the badge on arrival (the promotion path is public; Trimi’s ~$99/$125 and CoreAge’s ~$99/$149 self-published claims are exactly the kind of thing that wins the day they verify); a failed re-audit — price drift, terms degradation, or disclosure regression at the next NexLife re-verification (due by September 28, 2026) vacates it; a structural change — any move off dose-proof flat or month-to-month ends the case that earned it. A badge that can’t be lost is marketing; this one has published exit conditions.
FAQ
Is the Editor’s Pick paid placement?
No — it’s a criteria-based editorial designation (audited tier, lowest verified twelve-month cost, dose-proof, clean exit, full disclosure), decided on published rules with a public dethronement clause. The site does earn affiliate commissions, disclosed adjacent to every partner link and on the ownership page.
Why not score providers out of 10?
Because a number implies a measurement, and most of this market can’t be measured yet — tier labels (audited, on-record, pending) say exactly what we know and how; a 7.6/10 says only that someone typed 7.6.
When is the Pick reviewed next?
Each audit cycle — the current holder’s re-verification is due by September 28, 2026, and any verified cheaper flat entrant triggers an immediate re-decision.